All In Biotech

Drug Trial Radar · NCT03498716

A Study Comparing Atezolizumab (Anti PD-L1 Antibody) In Combination With Adjuvant Anthracycline/Taxane-Based Chemotherapy Versus Chemotherapy Alone In Patients With Operable Triple-Negative Breast Cancer

A Phase III, Multicenter, Randomized, Open-Label Study Comparing Atezolizumab (Anti PD-L1 Antibody) in Combination With Adjuvant Anthracycline/Taxane-Based Chemotherapy Versus Chemotherapy Alone in Patients With Operable Triple Negative Breast Cancer

Last checked: Nov 19, 2026Latest source record: Aug 21, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

TerminatedResults posted on the registryPivotal-lookingPhase 3. Randomized with 2,199 participants. This is a heuristic, not a regulatory label.

Status

Terminated

Enrollment

2,199

Actual

Start

Aug 2, 2018

Primary completion

Aug 14, 2023

Study completion Aug 14, 2023

Sponsor

Lead sponsor
Hoffmann-La RocheRoche (Genentech) (RHHBY)
Sponsor type
Industry
Collaborators
Breast International Group; Alliance Foundation Trials, LLC.; Jules Bordet Institute; Frontier Science & Technology Research Foundation, Inc.
First posted
Apr 17, 2018

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study will evaluate the efficacy, safety, and pharmacokinetics of adjuvant atezolizumab in combination with paclitaxel, followed by atezolizumab, dose-dense doxorubicin or epirubicin (investigator's choice), and cyclophosphamide, compared with paclitaxel followed by dose-dense doxorubicin or epirubicin (investigator's choice) and cyclophosphamide alone in patients with Stage II-III TNBC (Triple Negative Breast Cancer)

Conditions

  • Triple Negative Breast Cancer

Interventions

  • AtezolizumabDrug

    Atezolizumab will be administered by IV, 840 mg every 2 weeks, for 10 doses. Atezolizumab maintenance will be administered by IV, 1200 mg every 3 weeks to complete 1 year

  • PaclitaxelDrug

    Paclitaxel will be administered by IV, 80 mg/m\^2 every week for 12 weeks.

  • Dose-dense Doxorubicin or dose-dense EpirubicinDrug

    Dose-dense doxorubicin will be administered by IV, 60 mg/m\^2 every 2 weeks for a total of 4 doses. Or Dose-dense epirubicin will be administered by IV, (90 mg/m\^2) every 2 weeks for a total of 4 doses

  • CyclophosphamideDrug

    Cyclophosphamide will be administered by IV, 600 mg/m\^2 every 2 weeks for 4 doses

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Invasive Disease-Free Survival (iDFS)Time frame: From randomization until the occurrence of an iDFS event or death from any cause, whichever occurred earlier (up to 5 years)

Locations

364 sites in 31 countries. Site status is shown where the registry gives one.

  • John Muir Health Clinical Research Center

    Concord, California

  • Cedars-Sinai Medical Center

    Los Angeles, California

  • Martin-O?Neil Cancer Center

    St. Helena, California

  • Baptist - MD Anderson Cancer Center

    Jacksonville, Florida

  • Advocate Illinois Masonic Outpatient Center for Advanced Care

    Chicago, Illinois

  • Des Moines Oncology Research Association

    Des Moines, Iowa

  • Cancer Center of Kansas

    Wichita, Kansas

  • University of Maryland Greenebaum Comprehensive Cancer Center

    Baltimore, Maryland

  • Fairview Southdale Medical Oncology Clinic

    Edina, Minnesota

  • HCA Midwest Division

    Kansas City, Missouri

  • New Hampshire Hematology Oncology

    Manchester, New Hampshire

  • Monter Cancer Center

    Lake Success, New York

  • Memorial Sloan Kettering Cancer Center

    New York, New York

  • Rochester General Hospital; Lipson Cancer and Blood Center

    Rochester, New York

  • SCRI

    Nashville, Tennessee

  • Intermountain Precision Genomics Cancer Research Clinic-Dixie

    St. George, Utah

  • St. Mary's Medical Center

    Huntington, West Virginia

  • Centro de Oncologia e; Investigacion Buenos Aires - COIBA

    Berazategui, Argentina

  • INSTITUTO DE INVESTIGACIONES METABOLICAS (IDIM); Oncology

    Ciudad Autonoma Buenos Aires, Argentina

  • Hospital Britanico de Buenos Aires

    Ciudad Autonoma Buenos Aires, Argentina

  • Clinica Universitaria Reina Fabiola

    Córdoba, Argentina

  • Centro Oncologico Riojano Integral (CORI)

    La Rioja, Argentina

  • Instituto de Oncología de Rosario

    Rosario, Argentina

  • Centro Medico San Roque

    San Miguel de Tucumán, Argentina

  • Fundación Ars Medica

    San Salvador de Jujuy, Argentina

  • Centro de Investigacion Clinica - Clinica Viedma S.A.; Oncology Department

    Viedma, Argentina

  • St Vincent's Hospital Sydney

    Darlinghurst, New South Wales, Australia

  • Lismore Base Hospital

    Lismore, New South Wales, Australia

  • Macquarie University Hospital

    Macquarie Park, New South Wales, Australia

  • Sydney Adventist Hospital

    Wahroonga, New South Wales, Australia

  • Icon Cancer Care Wesley

    Auchenflower, Queensland, Australia

  • Icon Cancer Foundation; Icon Cancer Care Chermside

    Chermside, Queensland, Australia

  • Icon Cancer Care South Brisbane

    South Brisbane, Queensland, Australia

  • Mater Hospital; Cancer Services

    South Brisbane, Queensland, Australia

  • Icon Cancer Foundation; Icon Cancer Care Southport

    Southport, Queensland, Australia

  • Princess Alexandra Hospital; Cancer Trials Unit

    Woolloongabba, Queensland, Australia

  • Royal Adelaide Hospital; Cancer Centre

    Adelaide, South Australia, Australia

  • Ashford Cancer Center Research

    Kurralta Park, South Australia, Australia

  • Monash Medical Centre

    Clayton, Victoria, Australia

  • Austin Hospital Olivia Newton John Cancer Centre

    Heidelberg, Victoria, Australia

Showing 40 of 364 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.